Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366704 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00366704 is a Phase 3 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 400 participants.
The verdict
NCT00366704, a Phase 3 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of bifeprunox or risperidone on the body weight of patients with schizophrenia.
Interventions
- DRUG risperidone
- DRUG bifeprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366704
The ClinicalTrials.gov registry entry for NCT00366704 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00366704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366704 about?
NCT00366704 is a clinical study titled "Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint". The purpose of this study is to determine the effect of bifeprunox or risperidone on the body weight of patients with schizophrenia.
What is the current status of trial NCT00366704?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2006-11. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00366704?
The interventions under investigation include: risperidone (DRUG), bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00366704?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.